Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Weiss v. Emergent Biosolutions, Inc. et al
Case Number:
8:21-cv-01368
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
June 21, 2021
Entwistle, Wolf Haldenstein Vie To Rep Emergent Investors
Entwistle & Cappucci LLP and Wolf Haldenstein Adler Freeman & Herz LLP are competing in Maryland federal court to represent a proposed class of investors in a consolidated action claiming that biopharmaceutical company Emergent BioSolutions Inc. misled the public about how prepared it was to handle a pair of high-profile deals to manufacture COVID-19 vaccines.
-
June 02, 2021
Emergent Faces Investor Suit Over Destroyed COVID Vaccines
Emergent Biosolutions and its top executives were hit with a proposed class action Wednesday brought by an investor alleging misrepresentations and omissions concerning quality control problems at the company's facility in Maryland culminated in the destruction of up to 100 million doses of Johnson & Johnson and AstraZeneca COVID-19 vaccines.